Abstract
We report the detection of OXA-181 carbapenemase in an azithromycin-resistant Shigella spp. bacteria in an immunocompromised patient. The emergence of OXA-181 in Shigella spp. bacteria raises concerns about the global dissemination of carbapenem resistance in Enterobacterales and its implications for the treatment of infections caused by Shigella bacteria.
Keywords:
Canada; India; OXA-181; OXA-48; OXA-48-like; Shigella flexneri; antimicrobial resistance; bacteria; beta-lactamases; carbapenemase; enteric infections.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Anti-Bacterial Agents* / pharmacology
-
Anti-Bacterial Agents* / therapeutic use
-
Azithromycin / pharmacology
-
Azithromycin / therapeutic use
-
Bacterial Proteins* / genetics
-
Bacterial Proteins* / metabolism
-
Drug Resistance, Bacterial
-
Dysentery, Bacillary* / diagnosis
-
Dysentery, Bacillary* / drug therapy
-
Dysentery, Bacillary* / microbiology
-
Humans
-
Immunocompromised Host
-
Male
-
Microbial Sensitivity Tests*
-
Shigella flexneri* / drug effects
-
Shigella flexneri* / enzymology
-
Shigella flexneri* / genetics
-
Shigella flexneri* / isolation & purification
-
beta-Lactamases* / genetics
-
beta-Lactamases* / metabolism
Substances
-
beta-Lactamases
-
carbapenemase
-
Bacterial Proteins
-
Anti-Bacterial Agents
-
Azithromycin